蛋白質(zhì)是生物功能的主要載體，如果能像基因測(cè)序一樣直接破譯蛋白的一級(jí)結(jié)構(gòu)，對(duì)了解生命活動(dòng)的分子機(jī)制具有重大意義。Rapid Novor一直致力于無(wú)需基因序列的蛋白從頭測(cè)序技術(shù)，是全球首個(gè)提供單克隆抗體自動(dòng)化測(cè)序服務(wù)的公司。目前Rapd Novor擁有全球最大的蛋白測(cè)序質(zhì)譜平臺(tái)，是蛋白從頭測(cè)序技術(shù)的領(lǐng)跑者。RapdNovor的蛋白從頭測(cè)序技術(shù)已被應(yīng)用于多發(fā)性骨髓瘤MRD監(jiān)測(cè)，可以直接對(duì)人血清高濃度單克隆免疫球蛋白進(jìn)行測(cè)序，并獲得美國(guó)CLIA臨床認(rèn)證。上海快序生物科技有限公司是加拿大Rapid Novor 的中國(guó)公司。快序生物在中國(guó)提供的服務(wù)包括:抗體測(cè)序，抗體發(fā)現(xiàn)，腫瘤新抗原鑒定服務(wù)等。
Rapid Novor Shanghai Kuaixu Biotechnologies Co., Ltd. )has the world's leading de novo protein sequencing technologyand is commited to the applicationof this technolosy in the medical field. De novo sequencing is a technique that does not rely on existing DNA or protein database information and directlydetermines the amino acid sequence of proteins. Based on this technology. Rapid Novor(Kuaikxu) has established a new platform for antibody discovery andneoantigen identification. The antibody discovery platform can directly sequence antibody proteins in the serum ofimmunized animals or humans to obtainnatural antibody sequences, thereby significantly shortening the cycle of antibody drug development. However, drect sequencing of the MHC-bound peptidesegmentto obtain the actualpresented neoantigen sequence completely changes the previous discovery mode of neoantigens, which was mainly predicted bythe gene sequencing and algorthm. Rapid Novor (Kuaixu) has always been commited to developing the next generation of protein sequencing technology todecode the immune system and benefit human health.
官網(wǎng)鏈接：https://www.kuaixu.com/